Ignite Creation Date:
2025-12-24 @ 5:43 PM
Ignite Modification Date:
2026-01-01 @ 3:52 PM
Study NCT ID:
NCT00724568
Status:
COMPLETED
Last Update Posted:
2017-06-02
First Post:
2008-04-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
Sponsor:
University of Michigan Rogel Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-05
Start Date Type:
None
Primary Completion Date:
2009-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2014-09-03
Completion Date Type:
ACTUAL
First Submit Date:
2008-04-11
First Submit QC Date:
None
Study First Post Date:
2008-07-29
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2014-09-03
Results First Submit QC Date:
None
Results First Post Date:
2014-09-10
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-05-03
Last Update Post Date:
2017-06-02
Last Update Post Date Type:
ACTUAL